Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pipeline Integration Leaves Merck's Backbone As Cardiovascular, Infectious Disease

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Merck & Co.'s new late-stage pipeline, which integrates Schering-Plough's assets, positions it as a leader in cardiovascular disease and infectious disease drug development. Other therapeutic areas in the lineup include oncology, central nervous system disorders, diabetes and vaccines, and new opportunities in women's health

You may also be interested in...

Merck/Schering: The Next Wave Of Consolidation

News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion

Merck Taking Aggressive Approach To Cardiovascular Development

Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts